{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T06:59:03Z","timestamp":1793343543654,"version":"4.5.0"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T00:00:00Z","timestamp":1732752000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T00:00:00Z","timestamp":1732752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Biol"],"DOI":"10.1186\/s12915-024-02075-w","type":"journal-article","created":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T06:06:30Z","timestamp":1732773990000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["The neglected burden of chronic hypoxia on the resistance of glioblastoma multiforme to first-line therapies"],"prefix":"10.1186","volume":"22","author":[{"given":"Jolie","family":"Bou-Gharios","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georges","family":"No\u00ebl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Burckel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,28]]},"reference":[{"issue":"10","key":"2075_CR1","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987\u201396.","journal-title":"N Engl J Med"},{"issue":"5","key":"2075_CR2","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","volume":"10","author":"R Stupp","year":"2009","unstructured":"Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459\u201366.","journal-title":"Lancet Oncol"},{"issue":"1","key":"2075_CR3","doi-asserted-by":"publisher","first-page":"12","DOI":"10.14791\/btrt.2022.10.e34","volume":"10","author":"CW Wee","year":"2022","unstructured":"Wee CW. Radiotherapy for newly diagnosed glioblastoma in the elderly: what is the standard? Brain Tumor Res Treat. 2022;10(1):12\u201321.","journal-title":"Brain Tumor Res Treat"},{"issue":"3","key":"2075_CR4","doi-asserted-by":"publisher","first-page":"542","DOI":"10.3390\/cancers13030542","volume":"13","author":"AL Chedeville","year":"2021","unstructured":"Chedeville AL, Madureira PA. The role of hypoxia in glioblastoma radiotherapy resistance. Cancers (Basel). 2021;13(3):542.","journal-title":"Cancers (Basel)."},{"issue":"8","key":"2075_CR5","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1007\/s00701-022-05192-z","volume":"164","author":"X Li","year":"2022","unstructured":"Li X, Jia Z, Yan Y. Efficacy and safety of tumor-treating fields in recurrent glioblastoma: a systematic review and meta-analysis. Acta Neurochir (Wien). 2022;164(8):1985\u201393.","journal-title":"Acta Neurochir (Wien)"},{"key":"2075_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.900377","volume":"13","author":"A Krigers","year":"2022","unstructured":"Krigers A, Pinggera D, Demetz M, Kornberger LM, Kerschbaumer J, Thome C, Freyschlag CF. The routine application of tumor-treating fields in the treatment of glioblastoma WHO degrees IV. Front Neurol. 2022;13: 900377.","journal-title":"Front Neurol"},{"issue":"23","key":"2075_CR7","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1001\/jama.2017.18718","volume":"318","author":"R Stupp","year":"2017","unstructured":"Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B, Toms S, Idbaih A, Ahluwalia MS, Fink K, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA. 2017;318(23):2306\u201316.","journal-title":"JAMA"},{"key":"2075_CR8","doi-asserted-by":"publisher","first-page":"1014455","DOI":"10.3389\/fonc.2022.1014455","volume":"12","author":"J Vymazal","year":"2022","unstructured":"Vymazal J, Kazda T, Novak T, Slanina P, Sroubek J, Klener J, Hrbac T, Syrucek M, Rulseh AM. Eighteen years\u2019 experience with tumor treating fields in the treatment of newly diagnosed glioblastoma. Front Oncol. 2022;12:1014455.","journal-title":"Front Oncol"},{"issue":"11","key":"2075_CR9","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1056\/NEJMoa1611977","volume":"376","author":"JR Perry","year":"2017","unstructured":"Perry JR, Laperriere N, O\u2019Callaghan CJ, Brandes AA, Menten J, Phillips C, Fay M, Nishikawa R, Cairncross JG, Roa W, et al. Short-course radiation plus temozolomide in elderly patients with glioblastoma. N Engl J Med. 2017;376(11):1027\u201337.","journal-title":"N Engl J Med"},{"issue":"9","key":"2075_CR10","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/S1470-2045(12)70265-6","volume":"13","author":"A Malmstrom","year":"2012","unstructured":"Malmstrom A, Gronberg BH, Marosi C, Stupp R, Frappaz D, Schultz H, Abacioglu U, Tavelin B, Lhermitte B, Hegi ME, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol. 2012;13(9):916\u201326.","journal-title":"Lancet Oncol"},{"issue":"35","key":"2075_CR11","doi-asserted-by":"publisher","first-page":"4145","DOI":"10.1200\/JCO.2015.62.6606","volume":"33","author":"W Roa","year":"2015","unstructured":"Roa W, Kepka L, Kumar N, Sinaika V, Matiello J, Lomidze D, Hentati D, Guedes de Castro D, Dyttus-Cebulok K, Drodge S, et al. International atomic energy agency randomized phase III study of radiation therapy in elderly and\/or frail patients with newly diagnosed glioblastoma multiforme. J Clin Oncol. 2015;33(35):4145\u201350.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2075_CR12","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s13014-020-01584-6","volume":"15","author":"JC Trone","year":"2020","unstructured":"Trone JC, Vallard A, Sotton S, Ben Mrad M, Jmour O, Magne N, Pommier B, Laporte S, Ollier E. Survival after hypofractionation in glioblastoma: a systematic review and meta-analysis. Radiat Oncol. 2020;15(1):145.","journal-title":"Radiat Oncol"},{"issue":"1","key":"2075_CR13","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jgo.2018.06.006","volume":"10","author":"KT Nead","year":"2019","unstructured":"Nead KT, Swisher-McClure S. Utilization of hypofractionated radiation therapy in older glioblastoma patients. J Geriatr Oncol. 2019;10(1):155\u20138.","journal-title":"J Geriatr Oncol"},{"issue":"3","key":"2075_CR14","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s11912-022-01201-7","volume":"24","author":"CA Yuen","year":"2022","unstructured":"Yuen CA, Barbaro M, Haggiagi A. Newly diagnosed glioblastoma in elderly patients. Curr Oncol Rep. 2022;24(3):325\u201334.","journal-title":"Curr Oncol Rep"},{"issue":"5","key":"2075_CR15","doi-asserted-by":"publisher","first-page":"38","DOI":"10.21037\/cco-22-76","volume":"11","author":"JK Matsui","year":"2022","unstructured":"Matsui JK, Perlow HK, Facer BD, McCalla A, Marrazzo L, Detti B, Scorsetti M, Clerici E, Scoccianti S, Navarria P, et al. Radiotherapy for elderly patients with glioblastoma: an assessment of hypofractionation and modern treatment techniques. Chin Clin Oncol. 2022;11(5):38.","journal-title":"Chin Clin Oncol"},{"key":"2075_CR16","doi-asserted-by":"crossref","unstructured":"Pouessel D, Mervoyer A, Larrieu-Ciron D, Cabarrou B, Attal J, Robert M, Frenel JS, Olivier P, Poublanc M, Mounier M, et al. Hypofractionnated stereotactic radiotherapy and anti-PDL1 durvalumab combination in recurrent glioblastoma: results of the phase I part of the phase I\/II STERIMGLI trial. J Clin Oncol. 2018;36(15_suppl):2046.","DOI":"10.1200\/JCO.2018.36.15_suppl.2046"},{"key":"2075_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-10-478","volume":"10","author":"SE Combs","year":"2010","unstructured":"Combs SE, Kieser M, Rieken S, Habermehl D, Jakel O, Haberer T, Nikoghosyan A, Haselmann R, Unterberg A, Wick W, et al. Randomized phase II study evaluating a carbon ion boost applied after combined radiochemotherapy with temozolomide versus a proton boost after radiochemotherapy with temozolomide in patients with primary glioblastoma: the CLEOPATRA trial. BMC Cancer. 2010;10: 478.","journal-title":"BMC Cancer"},{"issue":"6","key":"2075_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-019-0235-1","volume":"51","author":"JW Lee","year":"2019","unstructured":"Lee JW, Ko J, Ju C, Eltzschig HK. Hypoxia signaling in human diseases and therapeutic targets. Exp Mol Med. 2019;51(6):1\u201313.","journal-title":"Exp Mol Med"},{"issue":"8","key":"2075_CR19","doi-asserted-by":"publisher","first-page":"339","DOI":"10.3390\/biom9080339","volume":"9","author":"K Saxena","year":"2019","unstructured":"Saxena K, Jolly MK. Acute vs. chronic vs. cyclic hypoxia: their differential dynamics, molecular mechanisms, and effects on tumor progression. Biomolecules. 2019;9(8):339.","journal-title":"Biomolecules"},{"issue":"7","key":"2075_CR20","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1093\/neuonc\/now258","volume":"19","author":"N Colwell","year":"2017","unstructured":"Colwell N, Larion M, Giles AJ, Seldomridge AN, Sizdahkhani S, Gilbert MR, Park DM. Hypoxia in the glioblastoma microenvironment: shaping the phenotype of cancer stem-like cells. Neuro Oncol. 2017;19(7):887\u201396.","journal-title":"Neuro Oncol"},{"issue":"1035","key":"2075_CR21","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20130676","volume":"87","author":"SR McKeown","year":"2014","unstructured":"McKeown SR. Defining normoxia, physoxia and hypoxia in tumours-implications for treatment response. Br J Radiol. 2014;87(1035): 20130676.","journal-title":"Br J Radiol"},{"key":"2075_CR22","doi-asserted-by":"publisher","first-page":"562","DOI":"10.3389\/fonc.2020.00562","volume":"10","author":"BS Sorensen","year":"2020","unstructured":"Sorensen BS, Horsman MR. Tumor hypoxia: impact on radiation therapy and molecular pathways. Front Oncol. 2020;10:562.","journal-title":"Front Oncol"},{"issue":"6","key":"2075_CR23","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.3390\/biomedicines10061285","volume":"10","author":"A Mosteiro","year":"2022","unstructured":"Mosteiro A, Pedrosa L, Ferres A, Diao D, Sierra A, Gonzalez JJ. The vascular microenvironment in glioblastoma: a comprehensive review. Biomedicines. 2022;10(6):1285.","journal-title":"Biomedicines"},{"key":"2075_CR24","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2147\/HP.S133231","volume":"5","author":"JC Forster","year":"2017","unstructured":"Forster JC, Harriss-Phillips WM, Douglass MJ, Bezak E. A review of the development of tumor vasculature and its effects on the tumor microenvironment. Hypoxia (Auckl). 2017;5:21\u201332.","journal-title":"Hypoxia (Auckl)"},{"key":"2075_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.853568","volume":"13","author":"B Gallez","year":"2022","unstructured":"Gallez B. The role of imaging biomarkers to guide pharmacological interventions targeting tumor hypoxia. Front Pharmacol. 2022;13: 853568.","journal-title":"Front Pharmacol"},{"issue":"2","key":"2075_CR26","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s10456-008-9099-z","volume":"11","author":"JA Nagy","year":"2008","unstructured":"Nagy JA, Benjamin L, Zeng H, Dvorak AM, Dvorak HF. Vascular permeability, vascular hyperpermeability and angiogenesis. Angiogenesis. 2008;11(2):109\u201319.","journal-title":"Angiogenesis"},{"issue":"6","key":"2075_CR27","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1158\/1078-0432.CCR-20-3580","volume":"27","author":"A Stadlbauer","year":"2021","unstructured":"Stadlbauer A, Kinfe TM, Eyupoglu I, Zimmermann M, Kitzwogerer M, Podar K, Buchfelder M, Heinz G, Oberndorfer S, Marhold F. Tissue hypoxia and alterations in microvascular architecture predict glioblastoma recurrence in humans. Clin Cancer Res. 2021;27(6):1641\u20139.","journal-title":"Clin Cancer Res"},{"key":"2075_CR28","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3389\/fonc.2016.00016","volume":"6","author":"A Liu","year":"2016","unstructured":"Liu A, Hou C, Chen H, Zong X, Zong P. Genetics and epigenetics of glioblastoma: applications and overall incidence of IDH1 mutation. Front Oncol. 2016;6:16.","journal-title":"Front Oncol"},{"issue":"10","key":"2075_CR29","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/s41389-021-00361-8","volume":"10","author":"X Fan","year":"2021","unstructured":"Fan X, Fan J, Yang H, Zhao C, Niu W, Fang Z, Chen X. Heterogeneity of subsets in glioblastoma mediated by Smad3 palmitoylation. Oncogenesis. 2021;10(10):72.","journal-title":"Oncogenesis"},{"issue":"1","key":"2075_CR30","doi-asserted-by":"publisher","first-page":"3288","DOI":"10.1038\/s41467-020-17139-y","volume":"11","author":"S Oh","year":"2020","unstructured":"Oh S, Yeom J, Cho HJ, Kim JH, Yoon SJ, Kim H, Sa JK, Ju S, Lee H, Oh MJ, et al. Integrated pharmaco-proteogenomics defines two subgroups in isocitrate dehydrogenase wild-type glioblastoma with prognostic and therapeutic opportunities. Nat Commun. 2020;11(1):3288.","journal-title":"Nat Commun"},{"issue":"6","key":"2075_CR31","doi-asserted-by":"publisher","first-page":"619","DOI":"10.3390\/biomedicines9060619","volume":"9","author":"A Vallee","year":"2021","unstructured":"Vallee A, Lecarpentier Y, Vallee JN. Opposed interplay between IDH1 mutations and the WNT\/beta-catenin pathway: added information for glioma classification. Biomedicines. 2021;9(6):619.","journal-title":"Biomedicines."},{"issue":"4","key":"2075_CR32","doi-asserted-by":"publisher","first-page":"469","DOI":"10.3390\/cancers11040469","volume":"11","author":"A D'Alessio","year":"2019","unstructured":"D\u2019Alessio A, Proietti G, Sica G, Scicchitano BM. Pathological and molecular features of glioblastoma and its peritumoral tissue. Cancers (Basel). 2019;11(4):469.","journal-title":"Cancers (Basel)."},{"issue":"1","key":"2075_CR33","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41467-021-27667-w","volume":"13","author":"KHB Lam","year":"2022","unstructured":"Lam KHB, Leon AJ, Hui W, Lee SC, Batruch I, Faust K, Klekner A, Hutoczki G, Koritzinsky M, Richer M, et al. Topographic mapping of the glioblastoma proteome reveals a triple-axis model of intra-tumoral heterogeneity. Nat Commun. 2022;13(1):116.","journal-title":"Nat Commun"},{"issue":"6","key":"2075_CR34","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1093\/neuonc\/nox191","volume":"20","author":"E Eskilsson","year":"2018","unstructured":"Eskilsson E, Rosland GV, Solecki G, Wang Q, Harter PN, Graziani G, Verhaak RGW, Winkler F, Bjerkvig R, Miletic H. EGFR heterogeneity and implications for therapeutic intervention in glioblastoma. Neuro Oncol. 2018;20(6):743\u201352.","journal-title":"Neuro Oncol"},{"issue":"22","key":"2075_CR35","doi-asserted-by":"publisher","first-page":"8471","DOI":"10.3390\/ijms21228471","volume":"21","author":"PC Pan","year":"2020","unstructured":"Pan PC, Magge RS. Mechanisms of EGFR resistance in glioblastoma. Int J Mol Sci. 2020;21(22):8471.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"2075_CR36","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1007\/s12035-020-01892-8","volume":"57","author":"BK Ahir","year":"2020","unstructured":"Ahir BK, Engelhard HH, Lakka SS. Tumor development and angiogenesis in adult brain tumor: glioblastoma. Mol Neurobiol. 2020;57(5):2461\u201378.","journal-title":"Mol Neurobiol"},{"issue":"4","key":"2075_CR37","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1093\/neuonc\/noab212","volume":"24","author":"JV Joseph","year":"2022","unstructured":"Joseph JV, Magaut CR, Storevik S, Geraldo LH, Mathivet T, Latif MA, Rudewicz J, Guyon J, Gambaretti M, Haukas F, et al. TGF-beta promotes microtube formation in glioblastoma through thrombospondin 1. Neuro Oncol. 2022;24(4):541\u201353.","journal-title":"Neuro Oncol"},{"issue":"1","key":"2075_CR38","first-page":"41","volume":"38","author":"G Sica","year":"2011","unstructured":"Sica G, Lama G, Anile C, Geloso MC, La Torre G, De Bonis P, Maira G, Lauriola L, Jhanwar-Uniyal M, Mangiola A. Assessment of angiogenesis by CD105 and nestin expression in peritumor tissue of glioblastoma. Int J Oncol. 2011;38(1):41\u20139.","journal-title":"Int J Oncol"},{"issue":"11","key":"2075_CR39","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1038\/s41416-020-0814-x","volume":"122","author":"S Han","year":"2020","unstructured":"Han S, Liu Y, Cai SJ, Qian M, Ding J, Larion M, Gilbert MR, Yang C. IDH mutation in glioma: molecular mechanisms and potential therapeutic targets. Br J Cancer. 2020;122(11):1580\u20139.","journal-title":"Br J Cancer"},{"key":"2075_CR40","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.semcancer.2017.11.010","volume":"51","author":"O Gusyatiner","year":"2018","unstructured":"Gusyatiner O, Hegi ME. Glioma epigenetics: from subclassification to novel treatment options. Semin Cancer Biol. 2018;51:50\u20138.","journal-title":"Semin Cancer Biol"},{"issue":"4","key":"2075_CR41","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3390\/cells6040045","volume":"6","author":"AR Monteiro","year":"2017","unstructured":"Monteiro AR, Hill R, Pilkington GJ, Madureira PA. The role of hypoxia in glioblastoma invasion. Cells. 2017;6(4):45.","journal-title":"Cells."},{"issue":"7","key":"2075_CR42","doi-asserted-by":"publisher","first-page":"799","DOI":"10.3390\/biomedicines9070799","volume":"9","author":"A Kayabolen","year":"2021","unstructured":"Kayabolen A, Yilmaz E, Bagci-Onder T. IDH mutations in glioma: double-edged sword in clinical applications? Biomedicines. 2021;9(7):799.","journal-title":"Biomedicines"},{"key":"2075_CR43","doi-asserted-by":"publisher","first-page":"16238","DOI":"10.1038\/srep16238","volume":"5","author":"P Kickingereder","year":"2015","unstructured":"Kickingereder P, Sahm F, Radbruch A, Wick W, Heiland S, Deimling A, Bendszus M, Wiestler B. IDH mutation status is associated with a distinct hypoxia\/angiogenesis transcriptome signature which is non-invasively predictable with rCBV imaging in human glioma. Sci Rep. 2015;5:16238.","journal-title":"Sci Rep"},{"issue":"13","key":"2075_CR44","doi-asserted-by":"publisher","first-page":"e2008772118","DOI":"10.1073\/pnas.2008772118","volume":"118","author":"AM Amen","year":"2021","unstructured":"Amen AM, Fellmann C, Soczek KM, Ren SM, Lew RJ, Knott GJ, Park JE, McKinney AM, Mancini A, Doudna JA, et al. Cancer-specific loss of TERT activation sensitizes glioblastoma to DNA damage. Proc Natl Acad Sci U S A. 2021;118(13):e2008772118.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"2075_CR45","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.trecan.2020.02.010","volume":"6","author":"M Butler","year":"2020","unstructured":"Butler M, Pongor L, Su YT, Xi L, Raffeld M, Quezado M, Trepel J, Aldape K, Pommier Y, Wu J. MGMT status as a clinical biomarker in glioblastoma. Trends Cancer. 2020;6(5):380\u201391.","journal-title":"Trends Cancer"},{"issue":"10","key":"2075_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2012.153","volume":"3","author":"L Persano","year":"2012","unstructured":"Persano L, Pistollato F, Rampazzo E, Della Puppa A, Abbadi S, Frasson C, Volpin F, Indraccolo S, Scienza R, Basso G. BMP2 sensitizes glioblastoma stem-like cells to temozolomide by affecting HIF-1alpha stability and MGMT expression. Cell Death Dis. 2012;3(10): e412.","journal-title":"Cell Death Dis"},{"issue":"5","key":"2075_CR47","doi-asserted-by":"publisher","DOI":"10.1177\/03000605211013774","volume":"49","author":"CQ Lin","year":"2021","unstructured":"Lin CQ, Chen LK. Effect of differential hypoxia-related gene expression on glioblastoma. J Int Med Res. 2021;49(5): 3000605211013774.","journal-title":"J Int Med Res"},{"issue":"3","key":"2075_CR48","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s13139-021-00693-8","volume":"55","author":"RA Abdo","year":"2021","unstructured":"Abdo RA, Lamare F, Fernandez P, Bentourkia M. Quantification of hypoxia in human glioblastoma using PET with 18F-FMISO. Nucl Med Mol Imaging. 2021;55(3):107\u201315.","journal-title":"Nucl Med Mol Imaging"},{"issue":"1","key":"2075_CR49","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41598-017-18310-0","volume":"8","author":"N Beig","year":"2018","unstructured":"Beig N, Patel J, Prasanna P, Hill V, Gupta A, Correa R, Bera K, Singh S, Partovi S, Varadan V, et al. Radiogenomic analysis of hypoxia pathway is predictive of overall survival in glioblastoma. Sci Rep. 2018;8(1):7.","journal-title":"Sci Rep"},{"issue":"4","key":"2075_CR50","first-page":"375","volume":"19","author":"Y Sun","year":"2019","unstructured":"Sun Y, Xiong ZY, Yan PF, Jiang LL, Nie CS, Wang X. Characteristics and prognostic factors of age-stratified high-grade intracranial glioma patients: a population-based analysis. Bosn J Basic Med Sci. 2019;19(4):375\u201383.","journal-title":"Bosn J Basic Med Sci"},{"issue":"1","key":"2075_CR51","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s11060-023-04479-0","volume":"165","author":"R Nakajima","year":"2023","unstructured":"Nakajima R, Kinoshita M, Okita H, Nakada M. Glioblastomas at the white matter of temporo-parietal junction cause a poor postoperative independence level. J Neurooncol. 2023;165(1):191\u20139.","journal-title":"J Neurooncol."},{"issue":"22","key":"2075_CR52","doi-asserted-by":"publisher","first-page":"12608","DOI":"10.3390\/ijms222212608","volume":"22","author":"M Domenech","year":"2021","unstructured":"Domenech M, Hernandez A, Plaja A, Martinez-Balibrea E, Balana C: Hypoxia: the cornerstone of glioblastoma. Int J Mol Sci 2021, 22(22):12608.","journal-title":"Int J Mol Sci"},{"key":"2075_CR53","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.drup.2019.04.002","volume":"43","author":"H Saleem","year":"2019","unstructured":"Saleem H, Kulsoom Abdul U, Kucukosmanoglu A, Houweling M, Cornelissen FMG, Heiland DH, Hegi ME, Kouwenhoven MCM, Bailey D, Wurdinger T, et al. The TICking clock of EGFR therapy resistance in glioblastoma: target independence or target compensation. Drug Resist Updat. 2019;43:29\u201337.","journal-title":"Drug Resist Updat"},{"key":"2075_CR54","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.637454","volume":"9","author":"J Zhang","year":"2021","unstructured":"Zhang J, Zhang Y, Mo F, Patel G, Butterworth K, Shao C, Prise KM. The roles of HIF-1alpha in radiosensitivity and radiation-induced bystander effects under hypoxia. Front Cell Dev Biol. 2021;9: 637454.","journal-title":"Front Cell Dev Biol"},{"issue":"12","key":"2075_CR55","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1002\/mc.23265","volume":"59","author":"T Matsumoto","year":"2020","unstructured":"Matsumoto T, Chino H, Akiya M, Hashimura M, Yokoi A, Tochimoto M, Nakagawa M, Jiang Z, Saegusa M. Requirements of LEFTY and Nodal overexpression for tumor cell survival under hypoxia in glioblastoma. Mol Carcinog. 2020;59(12):1409\u201319.","journal-title":"Mol Carcinog"},{"issue":"8","key":"2075_CR56","doi-asserted-by":"publisher","first-page":"7047","DOI":"10.3390\/ijms24087047","volume":"24","author":"JI Erices","year":"2023","unstructured":"Erices JI, Bizama C, Niechi I, Uribe D, Rosales A, Fabres K, Navarro-Martinez G, Torres A, San Martin R, Roa JC, et al. Glioblastoma microenvironment and invasiveness: new insights and therapeutic targets. Int J Mol Sci. 2023;24(8):7047.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"2075_CR57","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.3390\/cancers15092613","volume":"15","author":"T Shi","year":"2023","unstructured":"Shi T, Zhu J, Zhang X, Mao X. The role of hypoxia and cancer stem cells in development of glioblastoma. Cancers (Basel). 2023;15(9):2613.","journal-title":"Cancers (Basel)."},{"issue":"24","key":"2075_CR58","doi-asserted-by":"publisher","first-page":"6140","DOI":"10.3390\/ijms20246140","volume":"20","author":"AA Tirpe","year":"2019","unstructured":"Tirpe AA, Gulei D, Ciortea SM, Crivii C, Berindan-Neagoe I. Hypoxia: overview on hypoxia-mediated mechanisms with a focus on the role of HIF genes. Int J Mol Sci. 2019;20(24):6140.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"2075_CR59","doi-asserted-by":"publisher","first-page":"942","DOI":"10.7150\/ijbs.65653","volume":"18","author":"M Wang","year":"2022","unstructured":"Wang M, Zhang C, Zheng Q, Ma Z, Qi M, Di G, Ling S, Xu H, Qi B, Yao C, et al. RhoJ facilitates angiogenesis in glioblastoma via JNK\/VEGFR2 mediated activation of PAK and ERK signaling pathways. Int J Biol Sci. 2022;18(3):942\u201355.","journal-title":"Int J Biol Sci"},{"issue":"8","key":"2075_CR60","doi-asserted-by":"publisher","first-page":"965","DOI":"10.3390\/biomedicines9080965","volume":"9","author":"G Maugeri","year":"2021","unstructured":"Maugeri G, D\u2019Amico AG, Saccone S, Federico C, Rasa DM, Caltabiano R, Broggi G, Giunta S, Musumeci G, D\u2019Agata V. Effect of PACAP on hypoxia-induced angiogenesis and epithelial-mesenchymal transition in glioblastoma. Biomedicines. 2021;9(8):965.","journal-title":"Biomedicines."},{"issue":"3","key":"2075_CR61","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.tibs.2015.12.001","volume":"41","author":"MV Liberti","year":"2016","unstructured":"Liberti MV, Locasale JW. The Warburg effect: how does it benefit cancer cells? Trends Biochem Sci. 2016;41(3):211\u20138.","journal-title":"Trends Biochem Sci"},{"issue":"2","key":"2075_CR62","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.bbrc.2018.06.092","volume":"503","author":"K Duan","year":"2018","unstructured":"Duan K, Liu ZJ, Hu SQ, Huo HY, Xu ZR, Ruan JF, Sun Y, Dai LP, Yan CB, Xiong W, et al. Lactic acid induces lactate transport and glycolysis\/OXPHOS interconversion in glioblastoma. Biochem Biophys Res Commun. 2018;503(2):888\u201394.","journal-title":"Biochem Biophys Res Commun"},{"key":"2075_CR63","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2020.620677","volume":"7","author":"C Olivier","year":"2020","unstructured":"Olivier C, Oliver L, Lalier L, Vallette FM. Drug resistance in glioblastoma: the two faces of oxidative stress. Front Mol Biosci. 2020;7: 620677.","journal-title":"Front Mol Biosci"},{"issue":"3","key":"2075_CR64","doi-asserted-by":"publisher","first-page":"252","DOI":"10.15252\/embj.201695204","volume":"36","author":"GL Semenza","year":"2017","unstructured":"Semenza GL. Hypoxia-inducible factors: coupling glucose metabolism and redox regulation with induction of the breast cancer stem cell phenotype. EMBO J. 2017;36(3):252\u20139.","journal-title":"EMBO J"},{"issue":"3","key":"2075_CR65","doi-asserted-by":"publisher","first-page":"214","DOI":"10.3390\/cells8030214","volume":"8","author":"I Mylonis","year":"2019","unstructured":"Mylonis I, Simos G, Paraskeva E. Hypoxia-inducible factors and the regulation of lipid metabolism. Cells. 2019;8(3):214.","journal-title":"Cells"},{"issue":"3","key":"2075_CR66","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202101736R","volume":"36","author":"X Jin","year":"2022","unstructured":"Jin X, Kuang Y, Li L, Li H, Zhao T, He Y, Di C, Kang J, Yuan L, Yu B, et al. A positive feedback circuit comprising p21 and HIF-1alpha aggravates hypoxia-induced radioresistance of glioblastoma by promoting Glut1\/LDHA-mediated glycolysis. FASEB J. 2022;36(3): e22229.","journal-title":"FASEB J"},{"issue":"11","key":"2075_CR67","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1038\/s41419-022-05389-1","volume":"13","author":"Y Liao","year":"2022","unstructured":"Liao Y, Luo Z, Lin Y, Chen H, Chen T, Xu L, Orgurek S, Berry K, Dzieciatkowska M, Reisz JA, et al. PRMT3 drives glioblastoma progression by enhancing HIF1A and glycolytic metabolism. Cell Death Dis. 2022;13(11):943.","journal-title":"Cell Death Dis"},{"key":"2075_CR68","unstructured":"Institute NC: NCI dictionary of cancer terms.\u00a0https:\/\/www.cancer.gov\/publications\/dictionaries\/cancer-terms\/def\/autophagyefinitionofautophagy."},{"issue":"11\u201312","key":"2075_CR69","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s10495-018-1480-9","volume":"23","author":"MA Taylor","year":"2018","unstructured":"Taylor MA, Das BC, Ray SK. Targeting autophagy for combating chemoresistance and radioresistance in glioblastoma. Apoptosis. 2018;23(11\u201312):563\u201375.","journal-title":"Apoptosis"},{"issue":"10","key":"2075_CR70","doi-asserted-by":"publisher","first-page":"e2434","DOI":"10.1038\/cddis.2016.318","volume":"7","author":"S Jawhari","year":"2016","unstructured":"Jawhari S, Ratinaud MH, Verdier M. Glioblastoma, hypoxia and autophagy: a survival-prone \u201cmenage-a-trois.\u201d Cell Death Dis. 2016;7(10):e2434.","journal-title":"Cell Death Dis"},{"issue":"1","key":"2075_CR71","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s13046-021-01897-8","volume":"40","author":"M Zhao","year":"2021","unstructured":"Zhao M, Zhang Y, Jiang Y, Wang K, Wang X, Zhou D, Wang Y, Yu R, Zhou X. YAP promotes autophagy and progression of gliomas via upregulating HMGB1. J Exp Clin Cancer Res. 2021;40(1):99.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"2075_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e12820","volume":"9","author":"J Wei","year":"2023","unstructured":"Wei J, Zhu K, Yang Z, Zhou Y, Xia Z, Ren J, Zhao Y, Wu G, Liu C. Hypoxia-induced autophagy is involved in radioresistance via HIF1A-associated Beclin-1 in glioblastoma multiforme. Heliyon. 2023;9(1): e12820.","journal-title":"Heliyon"},{"issue":"4","key":"2075_CR73","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1152\/jn.00316.2022","volume":"128","author":"W Nie","year":"2022","unstructured":"Nie W, Luo X, Lu D, Yuan P, Liu B, Xu H, Ye M. Casein kinase 1alpha 1 is involved in the progression of glioblastoma through HIF-1alpha-mediated autophagy. J Neurophysiol. 2022;128(4):910\u20138.","journal-title":"J Neurophysiol"},{"issue":"1","key":"2075_CR74","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/s41388-018-0423-9","volume":"38","author":"J Feng","year":"2019","unstructured":"Feng J, Zhang Y, She X, Sun Y, Fan L, Ren X, Fu H, Liu C, Li P, Zhao C, et al. Hypermethylated gene ANKDD1A is a candidate tumor suppressor that interacts with FIH1 and decreases HIF1alpha stability to inhibit cell autophagy in the glioblastoma multiforme hypoxia microenvironment. Oncogene. 2019;38(1):103\u201319.","journal-title":"Oncogene"},{"issue":"1","key":"2075_CR75","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13045-021-01102-5","volume":"14","author":"XC Ding","year":"2021","unstructured":"Ding XC, Wang LL, Zhang XD, Xu JL, Li PF, Liang H, Zhang XB, Xie L, Zhou ZH, Yang J, et al. The relationship between expression of PD-L1 and HIF-1alpha in glioma cells under hypoxia. J Hematol Oncol. 2021;14(1):92.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2075_CR76","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11060-020-03483-y","volume":"151","author":"MM Grabowski","year":"2021","unstructured":"Grabowski MM, Sankey EW, Ryan KJ, Chongsathidkiet P, Lorrey SJ, Wilkinson DS, Fecci PE. Immune suppression in gliomas. J Neurooncol. 2021;151(1):3\u201312.","journal-title":"J Neurooncol"},{"key":"2075_CR77","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.914236","volume":"13","author":"Y Xiao","year":"2022","unstructured":"Xiao Y, Wang Z, Zhao M, Deng Y, Yang M, Su G, Yang K, Qian C, Hu X, Liu Y, et al. Single-cell transcriptomics revealed subtype-specific tumor immune microenvironments in human glioblastomas. Front Immunol. 2022;13: 914236.","journal-title":"Front Immunol"},{"issue":"6","key":"2075_CR78","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1158\/2326-6066.CIR-21-0559","volume":"10","author":"W Xuan","year":"2022","unstructured":"Xuan W, Hsu WH, Khan F, Dunterman M, Pang L, Wainwright DA, Ahmed AU, Heimberger AB, Lesniak MS, Chen P. Circadian regulator CLOCK drives immunosuppression in glioblastoma. Cancer Immunol Res. 2022;10(6):770\u201384.","journal-title":"Cancer Immunol Res"},{"issue":"23","key":"2075_CR79","doi-asserted-by":"publisher","first-page":"5876","DOI":"10.1158\/0008-5472.CAN-21-1456","volume":"81","author":"F Dong","year":"2021","unstructured":"Dong F, Qin X, Wang B, Li Q, Hu J, Cheng X, Guo D, Cheng F, Fang C, Tan Y, et al. ALKBH5 facilitates hypoxia-induced paraspeckle assembly and IL8 secretion to generate an immunosuppressive tumor microenvironment. Cancer Res. 2021;81(23):5876\u201388.","journal-title":"Cancer Res"},{"key":"2075_CR80","doi-asserted-by":"publisher","first-page":"1051701","DOI":"10.3389\/fimmu.2022.1051701","volume":"13","author":"L Ni","year":"2022","unstructured":"Ni L, Sun P, Zhang S, Qian B, Chen X, Xiong M, Li B. Transcriptome and single-cell analysis reveal the contribution of immunosuppressive microenvironment for promoting glioblastoma progression. Front Immunol. 2022;13:1051701.","journal-title":"Front Immunol"},{"key":"2075_CR81","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.canlet.2021.12.008","volume":"527","author":"A Hernandez Martinez","year":"2022","unstructured":"Hernandez Martinez A, Madurga R, Garcia-Romero N, Ayuso-Sacido A. Unravelling glioblastoma heterogeneity by means of single-cell RNA sequencing. Cancer Lett. 2022;527:66\u201379.","journal-title":"Cancer Lett"},{"issue":"19","key":"2075_CR82","doi-asserted-by":"publisher","first-page":"4852","DOI":"10.3390\/cancers14194852","volume":"14","author":"A Gozdz","year":"2022","unstructured":"Gozdz A, Wojtas B, Szpak P, Szadkowska P, Czernicki T, Marchel A, Wojtowicz K, Kaspera W, Ladzinski P, Szopa W, et al. Preservation of the hypoxic transcriptome in glioblastoma patient-derived cell lines maintained at lowered oxygen tension. Cancers (Basel). 2022;14(19):4852.","journal-title":"Cancers (Basel)."},{"issue":"7","key":"2075_CR83","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1016\/j.celrep.2017.07.049","volume":"20","author":"E Johansson","year":"2017","unstructured":"Johansson E, Grassi ES, Pantazopoulou V, Tong B, Lindgren D, Berg TJ, Pietras EJ, Axelson H, Pietras A. CD44 interacts with HIF-2alpha to modulate the hypoxic phenotype of perinecrotic and perivascular glioma cells. Cell Rep. 2017;20(7):1641\u201353.","journal-title":"Cell Rep"},{"issue":"2","key":"2075_CR84","first-page":"199","volume":"3","author":"LM Nusblat","year":"2020","unstructured":"Nusblat LM, Tanna S, Roth CM. Gene silencing of HIF-2alpha disrupts glioblastoma stem cell phenotype. Cancer Drug Resist. 2020;3(2):199\u2013208.","journal-title":"Cancer Drug Resist"},{"key":"2075_CR85","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.ebiom.2019.03.064","volume":"42","author":"R Tejero","year":"2019","unstructured":"Tejero R, Huang Y, Katsyv I, Kluge M, Lin JY, Tome-Garcia J, Daviaud N, Wang Y, Zhang B, Tsankova NM, et al. Gene signatures of quiescent glioblastoma cells reveal mesenchymal shift and interactions with niche microenvironment. EBioMedicine. 2019;42:252\u201369.","journal-title":"EBioMedicine"},{"issue":"3","key":"2075_CR86","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.3892\/ol.2016.4113","volume":"11","author":"Y Iwadate","year":"2016","unstructured":"Iwadate Y. Epithelial-mesenchymal transition in glioblastoma progression. Oncol Lett. 2016;11(3):1615\u201320.","journal-title":"Oncol Lett"},{"issue":"2","key":"2075_CR87","doi-asserted-by":"publisher","first-page":"741","DOI":"10.3390\/ijms23020741","volume":"23","author":"M Carcelen","year":"2022","unstructured":"Carcelen M, Velasquez C, Vidal V, Gutierrez O, Fernandez-Luna JL. HIF2alpha upregulates the migration factor ODZ1 under hypoxia in glioblastoma stem cells. Int J Mol Sci. 2022;23(2):741.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"2075_CR88","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41419-023-05788-y","volume":"14","author":"XG Mao","year":"2023","unstructured":"Mao XG, Xue XY, Lv R, Ji A, Shi TY, Chen XY, Jiang XF, Zhang X. CEBPD is a master transcriptional factor for hypoxia regulated proteins in glioblastoma and augments hypoxia induced invasion through extracellular matrix-integrin mediated EGFR\/PI3K pathway. Cell Death Dis. 2023;14(4):269.","journal-title":"Cell Death Dis"},{"issue":"11","key":"2075_CR89","doi-asserted-by":"publisher","first-page":"3744","DOI":"10.7150\/thno.81407","volume":"13","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Zhang B, Lv C, Zhang N, Xing K, Wang Z, Lv R, Yu M, Xu C, Wang Y. Single-cell RNA sequencing identifies critical transcription factors of tumor cell invasion induced by hypoxia microenvironment in glioblastoma. Theranostics. 2023;13(11):3744\u201360.","journal-title":"Theranostics"},{"issue":"7","key":"2075_CR90","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41419-024-06904-2","volume":"15","author":"J Bou-Gharios","year":"2024","unstructured":"Bou-Gharios J, Noel G, Burckel H. Preclinical and clinical advances to overcome hypoxia in glioblastoma multiforme. Cell Death Dis. 2024;15(7):503.","journal-title":"Cell Death Dis"},{"issue":"5","key":"2075_CR91","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.3390\/cancers14051259","volume":"14","author":"L Davis","year":"2022","unstructured":"Davis L, Recktenwald M, Hutt E, Fuller S, Briggs M, Goel A, Daringer N. Targeting HIF-2alpha in the tumor microenvironment: redefining the role of HIF-2alpha for solid cancer therapy. Cancers (Basel). 2022;14(5):1259.","journal-title":"Cancers (Basel)."},{"issue":"1","key":"2075_CR92","doi-asserted-by":"publisher","first-page":"17170","DOI":"10.1038\/s41598-021-95980-x","volume":"11","author":"YD Wen","year":"2021","unstructured":"Wen YD, Zhu XS, Li DJ, Zhao Q, Cheng Q, Peng Y. Proteomics-based prognostic signature and nomogram construction of hypoxia microenvironment on deteriorating glioblastoma (GBM) pathogenesis. Sci Rep. 2021;11(1):17170.","journal-title":"Sci Rep"},{"issue":"1","key":"2075_CR93","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s40478-024-01740-z","volume":"12","author":"KG de Oliveira","year":"2024","unstructured":"de Oliveira KG, Bang-Rudenstam A, Beyer S, Boukredine A, Talbot H, Governa V, Johansson MC, Mansson AS, Forsberg-Nilsson K, Bengzon J, et al. Decoding of the surfaceome and endocytome in primary glioblastoma cells identifies potential target antigens in the hypoxic tumor niche. Acta Neuropathol Commun. 2024;12(1):35.","journal-title":"Acta Neuropathol Commun"},{"issue":"9","key":"2075_CR94","doi-asserted-by":"publisher","first-page":"pgae355","DOI":"10.1093\/pnasnexus\/pgae355","volume":"3","author":"J Cha","year":"2024","unstructured":"Cha J, Ding EA, Carvalho EM, Fowler A, Aghi MK, Kumar S. Collagen VI deposition primes the glioblastoma microenvironment for invasion through mechanostimulation of beta-catenin signaling. PNAS Nexus. 2024;3(9):pgae355.","journal-title":"PNAS Nexus"},{"key":"2075_CR95","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.841890","volume":"12","author":"RA Ganesh","year":"2022","unstructured":"Ganesh RA, Sonpatki P, Naik D, John AE, Sathe G, Lakshmikantha A, Chandrachari KP, Bauer L, Knauper V, Aeschlimann D, et al. Multi-omics analysis of glioblastoma and glioblastoma cell line: molecular insights into the functional role of GPR56 and TG2 in mesenchymal transition. Front Oncol. 2022;12: 841890.","journal-title":"Front Oncol"},{"issue":"3","key":"2075_CR96","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s11060-019-03262-4","volume":"144","author":"V Indira Chandran","year":"2019","unstructured":"Indira Chandran V, Welinder C, Goncalves de Oliveira K, Cerezo-Magana M, Mansson AS, Johansson MC, Marko-Varga G, Belting M. Global extracellular vesicle proteomic signature defines U87-MG glioma cell hypoxic status with potential implications for non-invasive diagnostics. J Neurooncol. 2019;144(3):477\u201388.","journal-title":"J Neurooncol"}],"container-title":["BMC Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12915-024-02075-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12915-024-02075-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12915-024-02075-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T07:04:12Z","timestamp":1732777452000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcbiol.biomedcentral.com\/articles\/10.1186\/s12915-024-02075-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,28]]},"references-count":96,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2075"],"URL":"https:\/\/doi.org\/10.1186\/s12915-024-02075-w","relation":{},"ISSN":["1741-7007"],"issn-type":[{"value":"1741-7007","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,28]]},"assertion":[{"value":"6 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"278"}}